Pacira Pharmaceuticals Inc. (NASDAQ:PCRX)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a note issued to investors on Tuesday. They currently have a $109.00 price target on the stock. Wedbush’s target price indicates a potential upside of 220.40% from the stock’s current price.
Other research analysts also recently issued research reports about the stock. Mizuho reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a report on Wednesday, June 22nd. Zacks Investment Research upgraded shares of Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 target price on the stock in a report on Tuesday, July 26th. Jefferies Group reiterated a “buy” rating and issued a $60.00 target price (down previously from $74.00) on shares of Pacira Pharmaceuticals in a report on Monday. Brean Capital reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a report on Friday, August 5th. Finally, Cowen and Company reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a report on Tuesday, September 20th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $72.83.
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded down 0.06% during midday trading on Tuesday, hitting $34.00. The stock had a trading volume of 752,945 shares. The firm has a 50 day moving average of $40.37 and a 200-day moving average of $44.72. The company’s market cap is $1.27 billion. Pacira Pharmaceuticals has a one year low of $31.08 and a one year high of $80.25.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Thursday, August 4th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.03 by $0.16. The firm had revenue of $69.60 million for the quarter, compared to the consensus estimate of $67.80 million. Pacira Pharmaceuticals had a negative net margin of 4.21% and a positive return on equity of 0.02%. The business’s quarterly revenue was up 17.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.20 EPS. On average, analysts forecast that Pacira Pharmaceuticals will post $0.44 earnings per share for the current fiscal year.
In other Pacira Pharmaceuticals news, President James S. Scibetta sold 25,000 shares of the business’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $45.21, for a total value of $1,130,250.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO David M. Stack sold 15,000 shares of the business’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $45.32, for a total transaction of $679,800.00. The disclosure for this sale can be found here. 6.90% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its position in Pacira Pharmaceuticals by 122.7% in the first quarter. BlackRock Inc. now owns 2,497 shares of the company’s stock worth $133,000 after buying an additional 1,376 shares during the period. US Bancorp DE raised its position in Pacira Pharmaceuticals by 8.5% in the second quarter. US Bancorp DE now owns 5,010 shares of the company’s stock worth $169,000 after buying an additional 394 shares during the period. Teacher Retirement System of Texas raised its position in Pacira Pharmaceuticals by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 5,184 shares of the company’s stock worth $175,000 after buying an additional 622 shares during the period. Westpac Banking Corp raised its position in Pacira Pharmaceuticals by 46.7% in the second quarter. Westpac Banking Corp now owns 5,877 shares of the company’s stock worth $198,000 after buying an additional 1,870 shares during the period. Finally, Tower Research Capital LLC TRC raised its position in Pacira Pharmaceuticals by 713.2% in the second quarter. Tower Research Capital LLC TRC now owns 5,936 shares of the company’s stock worth $200,000 after buying an additional 5,206 shares during the period.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.
Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.